about
Is cardiac magnetic resonance imaging causing DNA damage?PET and SPECT in low-grade glioma.Functional evaluation of microvascular free flaps with positron emission tomography.Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data.PET imaging of blood flow and glucose metabolism in localized musculoskeletal tumors of the extremities.Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial.Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PETEvaluation of repeated [(18)F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomasSomatostatin receptor subtype 2 in high-grade gliomas: PET/CT with (68)Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapyProposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism.Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer.Clinical PET imaging of insulinoma and beta-cell hyperplasia.18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.Outcome of nasopharyngeal carcinoma in Finland: A nationwide study.Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records.Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma.Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.Radiotherapy volume delineation using dynamic [18F]-FDG PET/CT imaging in patients with oropharyngeal cancer: a pilot study.Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy.Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.Permanent in vitro growth is associated with poor prognosis in head and neck cancer.Patient Education Process in Oncologic Context: What, Why, and by Whom?Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy.Metabolic imaging by positron emission tomography in oncology.Uptake of [(18)F]EF5 as a Tracer for Hypoxic and Aggressive Phenotype in Experimental Head and Neck Squamous Cell Carcinoma.Expression of glucose transporters in head-and-neck tumors.Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy.Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer.Evaluation of different mathematical models for diffusion-weighted imaging of normal prostate and prostate cancer using high b-values: a repeatability study.Uptake of [N-methyl-11C]alpha-methylaminoisobutyric acid in untreated head and neck cancer studied by PET.The limitations of tissue-oxygen measurement and positron emission tomography as additional methods for postoperative breast reconstruction free-flap monitoring.Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS.Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose.Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium.Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
P50
Q22066044-3B1FDB8D-FACD-4C0A-9C4F-A163F472E3B2Q31012113-86BF1118-D1B1-4074-B90D-D85B6A10BB0FQ31040926-9B6D98D2-C937-4C6C-8144-192486F8181EQ33523536-2D54CD8C-32ED-4BFB-AFED-6B240B72D3AFQ33818852-FA1431F7-AD30-4065-827F-5FBC6C934511Q34163118-CBC3F6D5-8FBA-4431-90F0-24B2DF449517Q34611044-4D892304-0615-43E8-AC49-CC682269466DQ35545964-B1656464-80F6-43FD-8A1E-671E120A460EQ35572487-0A3223C7-C5AD-462D-8D87-58EA0B126D76Q36482484-059EC29E-2962-4193-B175-4D8417B47383Q36617954-74A82C35-005D-4DF7-BF65-291FA586C529Q37141969-5E2748B9-5C29-438B-86F3-26529FB913D6Q37690782-2E1C3333-FD9C-46F9-A3FC-E6D64A74F907Q38230178-E1727926-3119-47C4-B536-386A24BE358BQ38689454-608A69E6-8D0E-4D12-B1AD-B1477027DED1Q38806908-55A497E3-81AF-4C92-8F2B-C734CAC2A046Q38947007-8C4C508E-73B4-42B5-84C8-D2D30532E4B4Q38981899-CC3E8D37-F70F-4EA6-A773-E1917C262EECQ39462100-9022C17B-C65D-4967-B139-AB1E9A15179EQ39568484-742194A4-E21B-47AD-96EB-E3FCE76952ACQ40061489-CC980761-2EB6-4717-BB99-6CBBDB158BF2Q40202321-A007A145-D769-4769-93F1-FAA494AFD809Q40314191-824246C9-5EE6-44CA-AB45-45EE5489DB67Q40568823-607AAA35-39DC-43CD-BE53-04739CB5D559Q40588381-E05B1A77-85E6-4D40-BF82-B439247FD8D6Q41513145-7AAB872E-006A-4F3E-9A5A-170ECA54CD3AQ41647714-BBF2A527-657B-4226-854B-E358674CF7FEQ41871576-AB75A240-F752-40EE-978F-AAA2660394F1Q42505365-2A189333-7FF4-44B9-8040-FDCD0F50A084Q42855248-CFBFB7E0-ADEB-412E-AA9B-521684ABD938Q43274242-A77031C5-8EA8-4A82-AA7C-6F8383200CC1Q43592726-CAB1364A-A682-44F1-992A-C4F266407397Q44250192-3A5B94CC-EF67-4663-84F1-B43383DD9351Q44258677-FDFE944B-C247-4201-97E3-9235D1E37293Q44442718-95984A14-D037-4848-ADEC-C8D4D95F1D8EQ44459995-A7F56956-9624-400F-BDE5-59484CFC7A3EQ44612229-CC04BD0A-24B3-418C-AF7A-3152D66A3D59Q44652565-9789A7F2-AB82-42E6-ACA9-6A1595D54251Q44662343-AFA8AFA2-D217-449B-8A8E-994FF478233BQ45061240-ADFC746D-4BE1-4E94-939A-E85FB5625F27
P50
description
researcher ORCID ID = 0000-0002-5878-4333
@en
wetenschapper
@nl
name
Heikki Minn
@ast
Heikki Minn
@en
Heikki Minn
@es
Heikki Minn
@nl
type
label
Heikki Minn
@ast
Heikki Minn
@en
Heikki Minn
@es
Heikki Minn
@nl
prefLabel
Heikki Minn
@ast
Heikki Minn
@en
Heikki Minn
@es
Heikki Minn
@nl
P31
P496
0000-0002-5878-4333